Display options
Cite
Hervieu A, Kermorgant S. The Role of PI3K in Met Driven Cancer: A Recap. Front Mol Biosci. 2018;5:86doi: 10.3389/fmolb.2018.00086.
Hervieu, A., & Kermorgant, S. (2018). The Role of PI3K in Met Driven Cancer: A Recap. Frontiers in molecular biosciences, 586. https://doi.org/10.3389/fmolb.2018.00086
Hervieu, Alexia, and Kermorgant, Stéphanie. "The Role of PI3K in Met Driven Cancer: A Recap." Frontiers in molecular biosciences vol. 5 (2018): 86. doi: https://doi.org/10.3389/fmolb.2018.00086
Hervieu A, Kermorgant S. The Role of PI3K in Met Driven Cancer: A Recap. Front Mol Biosci. 2018 Oct 24;5:86. doi: 10.3389/fmolb.2018.00086. eCollection 2018. PMID: 30406111; PMCID: PMC6207648.
Copy Download .nbib Format: NLM
Share it on

Front Mol Biosci. 2018 Oct 24;5:86. doi: 10.3389/fmolb.2018.00086. eCollection 2018.

The Role of PI3K in Met Driven Cancer: A Recap.

Frontiers in molecular biosciences

Alexia Hervieu, Stéphanie Kermorgant

Affiliations

  1. Signal Transduction and Molecular Pharmacology Team, Cancer Therapeutics Division, Institute of Cancer Research, Sutton, United Kingdom.
  2. Spatial Signalling Team, Centre for Tumor Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

PMID: 30406111 PMCID: PMC6207648 DOI: 10.3389/fmolb.2018.00086

Abstract

The Receptor Tyrosine Kinase (RTK) Met, overexpressed or mutated in cancer, plays a major role in cancer progression and represents an attractive target for cancer therapy. However RTK inhibitors can lead to drug resistance, explaining the necessity to develop therapies that target downstream signaling. Phosphatidylinositide 3-kinase (PI3K) is one of the most deregulated pathways in cancer and implicated in various types of cancer. PI3K signaling is also a major signaling pathway downstream of RTK, including Met. PI3K major effectors include Akt and "mechanistic Target of Rapamycin" (mTOR), which each play key roles in numerous and various cell functions. Advancements made due to the development of molecular and pharmaceutical tools now allow us to delve into the roles of each independently. In this review, we summarize the current understanding we possess of the activation and role of PI3K/Akt/mTOR, downstream of Met, in cancer.

Keywords: Akt; Met; PI3K; cancer; mTOR; signaling

References

  1. Oncogene. 2003 May 8;22(18):2812-22 - PubMed
  2. J Biol Chem. 2007 Oct 19;282(42):30643-57 - PubMed
  3. Nat Cell Biol. 2002 Sep;4(9):658-65 - PubMed
  4. Nat Cell Biol. 2011 Jun 05;13(7):827-37 - PubMed
  5. Cell. 2008 May 2;133(3):486-97 - PubMed
  6. Cancer Metastasis Rev. 2008 Mar;27(1):85-94 - PubMed
  7. Mol Cell Biol. 2002 Oct;22(20):7279-90 - PubMed
  8. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12039-44 - PubMed
  9. Nature. 1995 Feb 23;373(6516):702-5 - PubMed
  10. PLoS One. 2014 Sep 15;9(9):e105919 - PubMed
  11. Nat Rev Clin Oncol. 2018 May;15(5):273-291 - PubMed
  12. Hepatology. 2007 May;45(5):1210-7 - PubMed
  13. J Biol Chem. 1996 May 31;271(22):13116-22 - PubMed
  14. J Cell Biol. 1998 Oct 19;143(2):533-45 - PubMed
  15. Oral Oncol. 2015 Feb;51(2):158-63 - PubMed
  16. Mol Cancer. 2014 Aug 07;13:185 - PubMed
  17. Cell. 2007 Jun 1;129(5):957-68 - PubMed
  18. Cell Death Differ. 2017 Jun;24(6):1045-1062 - PubMed
  19. Cancer Res. 2010 Oct 1;70(19):7580-90 - PubMed
  20. EMBO J. 1997 May 15;16(10):2634-45 - PubMed
  21. Mol Cell Biol. 1995 Feb;15(2):1110-22 - PubMed
  22. Traffic. 2001 Jan;2(1):12-8 - PubMed
  23. J Biol Chem. 1994 Jan 21;269(3):1815-20 - PubMed
  24. Mol Cell Biol. 1993 Aug;13(8):4600-8 - PubMed
  25. J Mol Signal. 2010 Jul 12;5:8 - PubMed
  26. Science. 2008 Sep 26;321(5897):1807-12 - PubMed
  27. Cancer Res. 2002 Jul 15;62(14):4132-41 - PubMed
  28. Cancer Res. 2014 Dec 1;74(23):6737-44 - PubMed
  29. Science. 2005 Feb 18;307(5712):1098-101 - PubMed
  30. Nature. 1995 Feb 23;373(6516):699-702 - PubMed
  31. Cell. 2008 Jul 11;134(1):135-47 - PubMed
  32. N Engl J Med. 2005 Nov 10;353(19):2012-24 - PubMed
  33. Development. 2009 Mar;136(5):843-53 - PubMed
  34. Nat Rev Cancer. 2018 Jun;18(6):341-358 - PubMed
  35. Mol Cancer. 2018 Feb 19;17(1):45 - PubMed
  36. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14417-22 - PubMed
  37. Carcinogenesis. 2010 Sep;31(9):1531-40 - PubMed
  38. Exp Cell Res. 2009 May 15;315(9):1601-9 - PubMed
  39. EMBO J. 1994 Feb 1;13(3):522-33 - PubMed
  40. J Cell Biol. 1995 Oct;131(1):215-26 - PubMed
  41. Nat Rev Cancer. 2012 Jan 24;12(2):89-103 - PubMed
  42. J Biol Chem. 1991 Nov 25;266(33):22087-90 - PubMed
  43. Mol Cell Biol. 1999 Mar;19(3):1784-99 - PubMed
  44. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Aug;120(2):238-47 - PubMed
  45. Mol Biol Cell. 1998 Aug;9(8):2185-200 - PubMed
  46. Nat Rev Cancer. 2009 Aug;9(8):550-62 - PubMed
  47. Cancer Cell. 2009 Dec 8;16(6):463-74 - PubMed
  48. J Cell Biol. 2008 Sep 8;182(5):855-63 - PubMed
  49. Science. 2007 Nov 16;318(5853):1108-13 - PubMed
  50. Nat Rev Cancer. 2002 Apr;2(4):289-300 - PubMed
  51. Cell Signal. 2006 Nov;18(11):1834-43 - PubMed
  52. J Biol Chem. 2017 Aug 18;292(33):13541-13550 - PubMed
  53. J Biol Chem. 2010 Feb 26;285(9):6377-89 - PubMed
  54. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1937-41 - PubMed
  55. J Cell Biol. 2007 Apr 9;177(1):151-62 - PubMed
  56. Nature. 2012 Jul 26;487(7408):500-4 - PubMed
  57. J Biol Chem. 2011 Apr 1;286(13):10998-1002 - PubMed
  58. Science. 1997 Apr 4;276(5309):60-6 - PubMed
  59. N Engl J Med. 2007 May 31;356(22):2271-81 - PubMed
  60. Nature. 1995 Aug 31;376(6543):768-71 - PubMed
  61. Development. 2007 Apr;134(7):1443-51 - PubMed
  62. J Biol Chem. 1998 Jan 2;273(1):200-6 - PubMed
  63. Nat Cell Biol. 2007 Mar;9(3):316-23 - PubMed
  64. Biochem J. 1997 Aug 15;326 ( Pt 1):139-47 - PubMed
  65. J Cell Biol. 2008 Sep 8;182(5):823-5 - PubMed
  66. Nature. 1994 Aug 18;370(6490):527-32 - PubMed
  67. Mol Cell. 2004 Oct 22;16(2):257-67 - PubMed
  68. Science. 1991 Feb 15;251(4995):802-4 - PubMed
  69. Oncogene. 2000 Nov 20;19(49):5582-9 - PubMed
  70. Science. 2004 Apr 23;304(5670):554 - PubMed
  71. Oncogene. 2005 Mar 3;24(10):1749-66 - PubMed
  72. Mol Biol Cell. 2000 May;11(5):1709-25 - PubMed
  73. Front Pharmacol. 2012 Sep 11;3:164 - PubMed
  74. Mol Cell. 2001 Nov;8(5):995-1004 - PubMed
  75. Nat Rev Mol Cell Biol. 2012 Feb 23;13(3):195-203 - PubMed
  76. J Cell Biol. 1992 Nov;119(3):629-41 - PubMed
  77. Pharmacol Ther. 2014 Jun;142(3):316-38 - PubMed
  78. Mol Cancer. 2017 May 22;16(1):93 - PubMed
  79. Cell. 2012 Apr 13;149(2):274-93 - PubMed
  80. Lancet. 2008 Aug 9;372(9637):449-56 - PubMed
  81. Am J Physiol. 1999 Oct;277(4):F624-33 - PubMed
  82. Science. 2007 May 18;316(5827):1039-43 - PubMed
  83. J Biol Chem. 2010 Feb 12;285(7):4511-9 - PubMed
  84. Cancer Discov. 2013 Jun;3(6):658-73 - PubMed
  85. Science. 2007 Oct 12;318(5848):287-90 - PubMed
  86. Trends Biochem Sci. 2007 Jul;32(7):342-9 - PubMed
  87. J Biol Chem. 2005 Feb 18;280(7):5350-60 - PubMed
  88. Nat Rev Mol Cell Biol. 2010 Feb;11(2):103-12 - PubMed
  89. Cell. 2004 Feb 6;116(3):445-56 - PubMed
  90. Nature. 2010 Jan 28;463(7280):464-73 - PubMed
  91. Cell Death Dis. 2013 May 09;4:e627 - PubMed
  92. Cell. 2005 Apr 22;121(2):179-93 - PubMed
  93. Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 - PubMed
  94. Nature. 1996 Nov 14;384(6605):173-6 - PubMed
  95. Mol Cell Biol. 2001 Aug;21(15):4968-84 - PubMed
  96. Eur J Cancer. 2010 Apr;46(6):1111-21 - PubMed
  97. N Engl J Med. 2014 Mar 13;370(11):997-1007 - PubMed
  98. Nat Cell Biol. 2002 Sep;4(9):648-57 - PubMed
  99. EMBO J. 2004 Oct 1;23(19):3721-34 - PubMed
  100. Cancer Res. 2001 Dec 15;61(24):8887-95 - PubMed
  101. Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1289-94 - PubMed
  102. Cancer Discov. 2017 Jul;7(7):666-669 - PubMed
  103. Mol Pharmacol. 2015;87(3):465-76 - PubMed
  104. Mol Biol Cell. 2016 Feb 15;27(4):702-15 - PubMed
  105. Nat Commun. 2014 May 19;5:3907 - PubMed
  106. J Biol Chem. 2003 Aug 1;278(31):28921-9 - PubMed
  107. Cancer Cell. 2007 Oct;12(4):395-402 - PubMed
  108. Nat Commun. 2016 Jul 22;7:12392 - PubMed
  109. Ann Oncol. 2017 Sep 1;28(9):2169-2178 - PubMed
  110. Cancer Res. 1984 Jan;44(1):1-10 - PubMed
  111. Oncogene. 1995 Apr 20;10(8):1631-8 - PubMed
  112. Nat Cell Biol. 2006 Nov;8(11):1303-9 - PubMed
  113. Mol Cell Biol. 2000 Nov;20(22):8513-25 - PubMed
  114. Cold Spring Harb Perspect Biol. 2013 Nov 01;5(11):a009035 - PubMed
  115. Cell. 1994 Apr 22;77(2):261-71 - PubMed
  116. J Clin Invest. 2008 Jul;118(7):2609-19 - PubMed
  117. Mol Cell. 2007 Mar 23;25(6):903-15 - PubMed
  118. J Clin Invest. 2002 Apr;109(7):863-7 - PubMed

Publication Types

Grant support